Key Financial Figures (Consolidated, ₹ lakhs)
H1 FY27 Performance:
- Revenue from operations: ₹3,107.00 lakhs, up 39.42% YoY from ₹2,228.57 lakhs in H1 FY26
- Other income: ₹18.07 lakhs, up 640.57% YoY from ₹2.44 lakhs
- Total income: ₹3,125.07 lakhs, up 40.07% YoY from ₹2,231.01 lakhs
- Total expenditure: ₹2,941.72 lakhs, up 53.60% YoY from ₹1,915.23 lakhs
- EBITDA: ₹183.35 lakhs, down 41.94% YoY from ₹315.78 lakhs
- EBITDA margin: 5.90%, down 810 bps from 14.00% in H1 FY26
- Depreciation: ₹59.32 lakhs, up 162.25% YoY from ₹22.62 lakhs
- Interest: ₹7.39 lakhs, down 80.86% YoY from ₹38.61 lakhs
- Profit before tax: ₹116.63 lakhs, down 54.18% YoY from ₹254.56 lakhs
- Tax: ₹44.86 lakhs, down 35.20% YoY from ₹69.23 lakhs
- PAT: ₹71.77 lakhs, down 61.27% YoY from ₹185.33 lakhs
- PAT margin: 2.30%, down 570 bps from 8.00% in H1 FY26
- EPS: ₹0.52, down 61.48% YoY from ₹1.35
Comparative Performance:
- H2 FY26 Revenue: ₹3,174.96 lakhs (H1 FY27 shows 2.14% decline sequentially)
- FY26 Full Year Revenue: ₹5,403.53 lakhs
- H2 FY26 PAT: ₹307.90 lakhs (H1 FY27 shows 76.69% decline sequentially)
- FY26 Full Year PAT: ₹493.23 lakhs
Revenue Mix (H1 FY27):
- Government business: 59.05%
- Private business: 40.95%
Balance Sheet Position (₹ lakhs)
As at 30 September 2026:
- Share capital: ₹1,375.39 lakhs (unchanged from 31 March 2026)
- Reserves: ₹5,119.00 lakhs (increased from ₹5,059.13 lakhs at 31 March 2026)
- Short-term borrowings: ₹122.32 lakhs (increased from ₹0.24 lakhs)
- Trade payables: ₹279.21 lakhs (increased from ₹180.09 lakhs)
- Other liabilities: ₹203.77 lakhs (decreased from ₹334.35 lakhs)
- Total liabilities: ₹7,099.69 lakhs (increased from ₹6,949.20 lakhs)
- Fixed assets: ₹947.26 lakhs (increased from ₹587.75 lakhs)
- Other non-current assets: ₹641.63 lakhs (increased from ₹194.25 lakhs)
- Trade receivables: ₹2,596.47 lakhs (increased from ₹2,106.90 lakhs)
- Other current assets: ₹2,914.33 lakhs (decreased from ₹4,060.30 lakhs)
- Total assets: ₹7,099.69 lakhs
Operational and Strategic Updates
Business Model Overview:
Earkart Limited operates as an integrated hearing healthcare platform spanning diagnostics, hearing aids, technology-enabled solutions and ENT pharmaceuticals. The company manufactures hearing aids under EQFY, Fame, Radius and Tiny brands at its Noida facility.
Shop-in-Shop (SIS) Clinic Network:
- 105 SIS clinics operational across 55+ cities in 24 states
- OMNI 2.0 remote audiometry technology enables one audiologist to serve 4-7 clinics remotely
- Clinics offer hearing tests, hearing aid fitting, and ENT pharmaceutical formulations
Technology Development:
- OMNI 2.0: Patented remote audiometry device (Indian patent granted October 2025)
- Capabilities include video otoscopy, air and bone conduction audiometry, tympanometry, OAE including newborn screening
- Can program Bluetooth-enabled and any programmable hearing aid of any brand in real time
- Portable with 11-inch display, wireless connectivity, and 8-hour battery life
Manufacturing Facility:
- Location: Noida, Uttar Pradesh
- Size: 13,000 sq ft (expanded from 4,500 sq ft at IPO)
- Installed capacity: 200,000 units per year with headroom for second shift
- Certifications: ISO 13485:2016, CDSCO-approved, BIS compliant
- Capabilities: End-to-end hearing aid production, in-house PCBA integration and testing
International Expansion:
- U.S. FDA registration completed for four hearing aid categories: Prescription, OTC, Wireless Prescription, and Wireless OTC
- Earkart Inc. (USA): Wholly-owned subsidiary for hearing-care distribution and services
- Earkart Health Limited (UK): 65% owned subsidiary for hearing-care distribution and services
- Current exports to Sri Lanka, Bangladesh, and Nepal
Subsidiary Structure:
- Earkart Pharmaceuticals Pvt. Ltd. (India, 100% owned): Pharma business
- 7 ENT pharmaceutical formulations launched: nasal sprays, tablets, capsules, and ear drops for nasal allergy, tinnitus, and earwax management
Government Business:
- Strong presence on Government e-Marketplace (GeM) portal
- Long-standing association with ALIMCO as a supplier
- Multiple ALIMCO orders secured
- Participation in government-led hearing healthcare programs
Recent Event Participation:
- Participated in ISOCON 2026 held in Amritsar on 9-10 October 2026
- Showcased hearing healthcare solutions, OMNI technology, and ENT pharmaceutical portfolio
- Engagement led by Mr. Rahul Salesha (Director) and Ms. Monika Misra (Promoter & Whole-Time Director)
Shareholding Pattern (as at 30 September 2026):
- Domestic institutions: 22.20%
- Retail and others: 20.45%
Company Background
- Incorporated: 2021
- Listed on BSE SME
- Conversion to public limited company: 2025
- Leadership team with 25+ years of experience